Correlation between low expression of protein disulfide isomerase A3 and lymph node metastasis in papillary thyroid carcinoma and poor prognosis: a clinicopathological study of 1,139 cases with long-term follow-up
Correlation between low expression of protein disulfide isomerase A3 and lymph node metastasis in papillary thyroid carcinoma and poor prognosis: a clinicopathological study of 1,139 cases with long-term follow-up
复制标题
DOI：
10.1507/endocrj.ej21-0394
复制
发表时间：
2021-11-02
影响因子：
2
通讯作者：
Ohashi, Ryuji
中科院分区：
文献类型：
--
作者：
Kure, Shoko;Chiba, Tomohiro;Ohashi, Ryuji
甲状腺乳头状癌（PTC）的发病率在世界范围内呈上升趋势。识别侵袭性PTC类型的生物标志物是有限的，这表明需要建立可靠的新型生物标志物。蛋白二硫异构酶A3 （PDIA3）是一种调节内质网中新合成的糖蛋白和应激反应蛋白折叠的伴侣蛋白。虽然PDIA3在乳腺癌、子宫颈、头颈部、胃肠道等多种癌症中的作用已被研究，但其在甲状腺癌中的表达尚未见报道。我们回顾性回顾了1139例PTC患者长期随访积累的资料，探讨了FTC患者PDIA3免疫组化表达与临床病理特征及预后的关系。ptc中PDIA3的表达明显低于正常甲状腺组织（NTT; n = 80, p = 0.002）。ptc中PDIA3低表达与淋巴结转移（p = 0.018）、阳性淋巴结数（p = 0.004）相关。PDIA3低表达患者的病因特异性生存率较PDIA3高表达患者差（p = 0.013）。我们的研究结果表明，低PDIA3表达与FTC患者临床预后差有关，PDIA3可能是一种新的辅助生物标志物。进一步阐明PDIA3在PTC中的生物学作用对未来的临床应用是有必要的。
The incidence of papillary thyroid carcinoma (PTC) is increasing worldwide. The biomarkers to identify aggressive types of PTC are limited, illustrating the need to establish reliable novel biomarkers. Protein disulfide isomerase A3 (PDIA3) is a chaperone protein that modulates the folding of newly synthesized glycoproteins and stress-responsive proteins in the endoplasmic reticulum. Although the role of PDIA3 in various cancers such as breast, uterine cervix, head and neck, and gastrointestinal tract has been examined, its expression in thyroid cancer has not been reported. We retrospectively reviewed accumulated data with long-term follow-up of 1,139 PTC patients, and investigated the correlation between immunohistochemical expression of PDIA3 in FTC patients and clinicopathological features and prognosis. PDIA3 expression was significantly lower in PTCs compared to normal thyroid tissues (NTT; n = 80, p = 0.002). In PTCs, correlation between low PDIA3 expression and lymph node metastasis (p = 0.018) and the number of positive nodes (p = 0.004) was observed. Patients with low PDIA3 expression exhibited worse cause-specific survival compared to those with high PDIA3 expression (p = 0.013). Our findings indicate that low PDIA3 expression is related to poor clinical outcome in FTC patients, and that PDIA3 may potentially be a novel ancillary biomarker. Further clarification of the biological role of PDIA3 in PTC is warranted for the future clinical application.